2023 World Conference on Lung Cancer (Posters)-EP08.03. Copy Number Variants and Late Somatic Mutations Underlying Tumor Progression in NADIM Clinical Trials

EP08.03. Copy Number Variants and Late Somatic Mutations Underlying Tumor Progression in NADIM Clinical Trials - PDF(Abstract)

Back to course

Pdf Summary

This study presented preliminary results on the potential molecular mechanisms underlying disease progression in patients with non-small cell lung cancer (NSCLC) treated with neoadjuvant nivolumab plus chemotherapy. The study analyzed plasma samples from patients included in the NADIM and NADIM II trials. Cell-free DNA was isolated from plasma samples and analyzed using the TruSight Oncology 500 ctDNA panel. Somatic variants were detected in 87.5% of the samples, and a wide molecular heterogeneity was observed. The most frequently mutated genes were TP53, SETBP1, and GRIN2A. Copy number variants in RET, EGFR, and FGFR were found in the plasma samples collected upon disease progression. The acquisition of these somatic-copy number alterations may have important implications for subsequent treatment selection. Neoadjuvant chemoimmunotherapy is the new standard of treatment for locally-advanced NSCLC patients, and understanding the molecular mechanisms underlying disease progression in these patients can help improve treatment strategies. This study provides insights into the genetic alterations that occur during tumor progression in NSCLC patients treated with neoadjuvant therapy, highlighting the importance of molecular profiling in guiding treatment decisions.

Asset Subtitle

Roberto Serna Blasco

Meta Tag

Speaker Roberto Serna Blasco

Topic Local-Regional NSCLC: Novel Therapies & Trials

Keywords

non-small cell lung cancer

NSCLC

neoadjuvant nivolumab

chemotherapy

plasma samples

somatic variants

molecular heterogeneity

copy number variants

disease progression

molecular profiling